Published in Cancer Weekly, December 7th, 2004
The data were presented at the 29th European Society of Medical Oncology (ESMO) meeting in Vienna, Austria.
Data from these phase I safety and pharmacokinetic (metabolism) interaction studies showed that BAY 43-9006 could be combined with the other anticancer agents evaluated (doxorubicin, oxaliplatin, fluorouracil and leucovorin).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.